Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers 475% More CBD to the Bloodstream
- LXRP’s DehydraTECH has been shown to outperform conventional cannabis formulations and deliver 475 percent more CBD to the bloodstream in the first 15 minutes
- Compared to other industry formulations, DehydraTECH delivered cannabinoids quicker at industry-leading volumes
- A DehydraTECH formulation achieved a 319 percent higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH delivery technology has demonstrated in animal lab tests that it can deliver cannabinoids to the bloodstream more quickly than conventional cannabinoid formulations (http://nnw.fm/fsKW4). At 15 minutes into the test, the DehydraTECH formulation achieved a blood concentration level that was 475 percent higher than a generic coconut oil formulation; at 60 minutes, the blood concentration level was 319 percent higher.
Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced flavor and aroma-profile masking techniques in the industry. The groundbreaking technology could negate the need for artificial chemical masking agents or flavoring agents/sweeteners that mask the bitter flavors and aromas of cannabis.
Over the entire 60 minutes of the study, the DehydraTECH LCFA formulation delivered a CBD blood concentration level that was 334 percent higher than the level identified in animals that received the MCT oil formulation. The lab tests on animals compared how quickly a DehydraTECH formulation containing LCFA could deliver cannabinoids to the bloodstream, as compared to a concentration-matched conventional industry cannabinoid edible formulation with MCT oil. Coconut oil is commonly used due to its luxurious taste and mouth-feel, which can hide unpleasant cannabis flavors.
The result is that, in the head-to-head animal absorption study, the coconut oil formulations delivered cannabinoids into animal bloodstreams poorly, at about one-fourth the rate of the patented Lexaria LCFA. The DehydraTECH formulation was shown to deliver CBD more quickly than MCT oil formulations to the 10 male Sprague-Dawley rats tested.
Not only is delivery to the bloodstream enhanced; eight hours into the study, brain tissue was sampled to quantify CBD delivery into the brain. The DehydraTECH-enabled formulation outperformed the MCT oil formulation by 246 percent. First discovered in two series of nicotine absorption tests in animals conducted in 2018, LXRP’s DehydraTECH continued to deliver a drug, both to the bloodstream and across the blood-brain barrier, more effectively than industry standards. As a result, the efficient delivery could mean increased consumer satisfaction and utilization of lower dosage quantities.
LXRP is a bioscience company with North American operations and a drug-delivery platform innovator. LXRP’s disruptive delivery technology, DeydraTECH, is out-licensed by the company. The technology is designed to promote healthier ingestion methods and lower overall dosing. LXRP is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and it has multiple patents pending in more than 40 countries worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- LXRP’s DehydraTECH has been shown to outperform conventional cannabis formulations and deliver 475 percent more CBD to the bloodstream in the first 15 minutes
- Compared to other industry formulations, DehydraTECH delivered cannabinoids quicker at industry-leading volumes
- A DehydraTECH formulation achieved a 319 percent higher CBD blood concentration level at 60 minutes than the generic coconut oil formulation
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH delivery technology has demonstrated in animal lab tests that it can deliver cannabinoids to the bloodstream more quickly than conventional cannabinoid formulations (http://nnw.fm/fsKW4). At 15 minutes into the test, the DehydraTECH formulation achieved a blood concentration level that was 475 percent higher than a generic coconut oil formulation; at 60 minutes, the blood concentration level was 319 percent higher.
Lab tests and actual licensed use in the cannabis industry have proved that DehydraTECH’s long-chain fatty acid (“LCFA”) formulation is able to deliver cannabinoids faster than formulations with medium-chain triglyceride (“MCT”) oils, such as coconut oil. DehydraTECH also offers the most advanced flavor and aroma-profile masking techniques in the industry. The groundbreaking technology could negate the need for artificial chemical masking agents or flavoring agents/sweeteners that mask the bitter flavors and aromas of cannabis.
Over the entire 60 minutes of the study, the DehydraTECH LCFA formulation delivered a CBD blood concentration level that was 334 percent higher than the level identified in animals that received the MCT oil formulation. The lab tests on animals compared how quickly a DehydraTECH formulation containing LCFA could deliver cannabinoids to the bloodstream, as compared to a concentration-matched conventional industry cannabinoid edible formulation with MCT oil. Coconut oil is commonly used due to its luxurious taste and mouth-feel, which can hide unpleasant cannabis flavors.
The result is that, in the head-to-head animal absorption study, the coconut oil formulations delivered cannabinoids into animal bloodstreams poorly, at about one-fourth the rate of the patented Lexaria LCFA. The DehydraTECH formulation was shown to deliver CBD more quickly than MCT oil formulations to the 10 male Sprague-Dawley rats tested.
Not only is delivery to the bloodstream enhanced; eight hours into the study, brain tissue was sampled to quantify CBD delivery into the brain. The DehydraTECH-enabled formulation outperformed the MCT oil formulation by 246 percent. First discovered in two series of nicotine absorption tests in animals conducted in 2018, LXRP’s DehydraTECH continued to deliver a drug, both to the bloodstream and across the blood-brain barrier, more effectively than industry standards. As a result, the efficient delivery could mean increased consumer satisfaction and utilization of lower dosage quantities.
LXRP is a bioscience company with North American operations and a drug-delivery platform innovator. LXRP’s disruptive delivery technology, DeydraTECH, is out-licensed by the company. The technology is designed to promote healthier ingestion methods and lower overall dosing. LXRP is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and it has multiple patents pending in more than 40 countries worldwide.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
